Lophius' technologies enable the pathogen-specific stimulation of a broad spectrum of clinically-relevant effector cells and the identification of markers secreted by these cells facilitating the development of novel molecular diagnostic solutions.
Our core program addresses an unmet clinical need in tuberculosis (TB), an often underestimated global epidemic. TB remains one of the 10 leading causes of death worldwide with around 1.5 million casualties each year.
We have successfully developedand and are already commercializing our clinically-validated CE-marked diagnostic kit T-Track® CMV to individualize transplant patient management by allowing personalized cytomegalovirus (CMV) disease risk stratification.
Our leadership team has a substantial track-record and strong network in the diagnostics industry. Together we strive to make a positive impact in the fight against life-threatening and highly-contagious infectious diseases.
Combining a deep understanding of the immune response and how to accurately analyze it in a diagnostic setting with strong molecular diagnostic capabilities, makes Lophius the ideal partner to develop truly novel diagnostic solutions.
Lophius is actively publishing and encourages its academic collaboration partners to publish research results. The company’s technologies and activities in CMV have resulted in a growing list of publications in peer-reviewed journals.